Acción AIM AIM IMMUNOTECH INC.
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas AIM ImmunoTech Inc.

Acciones

AIM

US00901B1052

Mercado cerrado - Nyse
Otros sitios de cotización
 22:00:00 06/05/2024 		Varia. Cinco días. Varia. 1 de enero.
0,42 USD +3,75 % Gráfico intradía de AIM ImmunoTech Inc. +1,97 % -4,52 %
29/04 AIM ImmunoTech dice que se ha completado la evaluación de seguridad del primer nivel de dosis del estudio sobre el cáncer de páncreas MT
10/04 AIM Immunotech anuncia datos provisionales positivos de primera línea y previstos en el protocolo del estudio de Ampligen combinado con pembrolizumab para el tratamiento del cáncer de ovario recurrente CI

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®
AIM ImmunoTech Says Safety Evaluation of First Dose Level of Pancreatic Cancer Study Completed
AIM ImmunoTech Announces First Dose Level is Generally Well-Tolerated in Phase 1b/2 Study of Ampligen and Imfinzi as a Combination Therapy for Late-Stage Pancreatic Cancer
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
AIM ImmunoTech Announces Charles Lapp, MD, as a Consulting Medical Officer for its ME/CFS and Long COVID Programs
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
AIM ImmunoTech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer
AIM Immunotech Announces Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen Combined with Pembrolizumab for the Treatment of Recurrent Ovarian Cancer
Challenges To Advance Notice Bylaws Are Spiking
AIM ImmunoTech Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
North American Morning Briefing : Stocks Seen -2-
AIM ImmunoTech Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
AIM ImmunoTech to Present at the MedInvest Biotech & Pharma Investor Conference
AIM ImmunoTech to Discuss Fourth Quarter and Full Year 2023 Financial Results on April 2, 2024, and Host Conference Call and Webcast
AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción AIM
  4. Noticias AIM ImmunoTech Inc.
  5. Otros idiomas